Rifaximin in the Treatment of Gastroesophageal Reflux Disease: A New Idea Based on the Relationship between Intestinal Microecology and Gastroesophageal Reflux Disease
Rifaximin in the Treatment of Gastroesophageal Reflux Disease (GERD) is a common clinical disorder, the most common symptom of which is a burning sensation behind the breastbone (heartburn) or reflux of stomach contents into the upper pharynx (acid reflux). The prevalence in China is increasing year by year, which can affect the quality of life of patients and also increase the economic burden on families and society. The pathogenesis of GERD is still unclear, and some studies suggest that intestinal microecology may be closely related to the development of GERD. Rifaximin is not readily absorbed orally and acts locally in the intestine, so it has mild adverse effects and good safety, and can be used to treat gastrointestinal diseases such as irritable bowel syndrome, traveler’s diarrhea, small intestinal bacterial overgrowth, diverticulosis, inflammatory bowel disease and hepatic encephalopathy. Therefore, this paper focuses on intestinal microecology as a possible pathogenesis of GERD and further explores the feasibility of rifaximin for the treatment of GERD.
References
[1]
Maret-Ouda, J., Markar, S.R. and Lagergren, J. (2020) Gastroesophageal Reflux Disease: A Review. JAMA, 324, 2536-2547. https://doi.org/10.1001/jama.2020.21360
[2]
Pan, G.Z., Xu, G.M., Guo, H.P., et al. (1999) Epidemiological Survey of Gastroesophageal Reflux Symptoms in Beijing and Shanghai. Chinese Journal of Gastroenterology, No. 4, 8-11. (In Chinese)
[3]
Xiong, L.S., Chen, M.H., Chen, H.X., et al. (2006) Epidemiological Study of Gastroesophageal Reflux Disease in a Community Population in Guangdong Province. Chinese Journal of Gastroenterology, No. 4, 239-242. (In Chinese)
[4]
Zheng, Z., Shang, Y., Wang, N., et al. (2021) Current Advancement on the Dynamic Mechanism of Gastroesophageal Reflux Disease. International Journal of Biological Sciences, 17, 4154-4164. https://doi.org/10.7150/ijbs.65066
[5]
Haworth, J.J., Boyle, N., Vales, A. and Hobson, R. (2021) The Prevalence of Intestinal Dysbiosis in Patients Referred for Antireflux Surgery. Surgical Endoscopy, 35, 7112-7119. https://doi.org/10.1007/s00464-020-08229-5
[6]
Elias, E. and Targownik, L.E. (2019) The Clinician’s Guide to Proton Pump Inhibitor Related Adverse Events. Drugs, 79, 715-731. https://doi.org/10.1007/s40265-019-01110-3
[7]
Vaezi, M.F., Yang, Y.-X. and Howden, C.W. (2017) Complications of Proton Pump Inhibitor Therapy. Gastroenterology, 153, 35-48. https://doi.org/10.1053/j.gastro.2017.04.047
[8]
Almario, C.V., Chey, W.D. and Spiegel, B.M.R. (2020) Increased Risk of COVID-19 among Users of Proton Pump Inhibitors. The American Journal of Gastroenterology, 115, 1707-1715. https://doi.org/10.14309/ajg.0000000000000798
[9]
Lin, S.-M., Yang, S.-H., Liang, C.-C. and Huang, H.-K. (2018) Proton Pump Inhibitor USE and the Risk of Osteoporosis and Fracture in Stroke Patients: A Population-Based Cohort Study. Osteoporosis International, 29, 153-162. https://doi.org/10.1007/s00198-017-4262-2
[10]
Gyawali, C.P., Kahrilas, P.J., Savarino, E., et al. (2018) Modern Diagnosis of GERD: The Lyon Consensus. Gut, 67, 1351-1362. https://doi.org/10.1136/gutjnl-2017-314722
[11]
Mittal, R. and Vaezi, M.F. (2020) Esophageal Motility Disorders and Gastroesophageal Reflux Disease. The New England Journal of Medicine, 383, 1961-1972. https://doi.org/10.1056/NEJMra2000328
[12]
Mittal, R.K. and Balaban, D.H. (1997) The Esophagogastric Junction. The New England Journal of Medicine, 336, 924-932. https://doi.org/10.1056/NEJM199703273361306
[13]
Kim, K.-M., Kim, B.-T., Lee, D.-J., et al. (2012) Erosive Esophagitis May Be Related to Small Intestinal Bacterial Overgrowth. Scandinavian Journal of Gastroenterology, 47, 493-498. https://doi.org/10.3109/00365521.2012.668932
[14]
Patcharatrakul, T., Linlawan, S., Plaidum, S. and Gonlachanvit, S. (2021) The Effect of Rice vs. Wheat Ingestion on Postprandial Gastroesophageal Reflux (GER) Symptoms in Patients with Overlapping GERD-Irritable Bowel Syndrome (IBS). Foods, 11, Article 26. https://doi.org/10.3390/foods11010026
[15]
Ropert, A., Cherbut, C., Roze, C., et al. (1996) Colonic Fermentation and Proximal Gastric Tone in Humans. Gastroenterology, 111, 289-296. https://doi.org/10.1053/gast.1996.v111.pm8690193
[16]
Plaidum, S., Patcharatrakul, T., Promjampa, W., et al. (2022) The Effect of Fermentable, Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAP) Meals on Transient Lower Esophageal Relaxations (TLESR) in Gastroesophageal Reflux Disease (GERD) Patients with Overlapping Irritable Bowel Syndrome (IBS). Nutrients, 14, Article 1755. https://doi.org/10.3390/nu14091755
[17]
Yuan, S. and Larsson, S.C. (2022) Adiposity, Diabetes, Lifestyle Factors and Risk of Gastroesophageal Reflux Disease: A Mendelian Randomization Study. European Journal of Epidemiology, 37, 747-754. https://doi.org/10.1007/s10654-022-00842-z
[18]
Katz, P.O., Gerson, L.B. and Vela, M.F. (2013) Corrigendum: Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. The American Journal of Gastroenterology, 108, 308-328. https://doi.org/10.14309/00000434-201310000-00036
[19]
Xiao, Y., Zhang, S., Dai, N., et al. (2020) Phase III, Randomised, Double-Blind, Multicentre Study to Evaluate the Efficacy and Safety of Vonoprazan Compared with Lansoprazole in Asian Patients with Erosive Oesophagitis. Gut, 69, 224-230. https://doi.org/10.1136/gutjnl-2019-318365
[20]
Heidelbaugh, J.J., Goldberg, K.L. and Inadomi, J.M. (2010) Magnitude and Economic Effect of Overuse of Antisecretory Therapy in the Ambulatory Care Setting. The American Journal of Managed Care, 16, e228-e234.
[21]
D’Silva, K.M., Mehta, R., Mitchell, M., et al. (2021) Proton Pump Inhibitor Use and Risk for Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. Clinical Microbiology and Infection, 27, 697-703. https://doi.org/10.1016/j.cmi.2021.01.008
[22]
Cryan, J.F., O’riordan, K.J., Cowan, C.S.M., et al. (2019) The Microbiota-Gut-Brain Axis. Physiological Reviews, 99, 1877-2013. https://doi.org/10.1152/physrev.00018.2018
[23]
Jackson, M.A., Goodrich, J.K., Maxan, M.-E., et al. (2016) Proton Pump Inhibitors Alter the Composition of the Gut Microbiota. Gut, 65, 749-756. https://doi.org/10.1136/gutjnl-2015-310861
[24]
Lo, W.-K. and Chan, W.W. (2013) Proton Pump Inhibitor Use and the Risk of Small Intestinal Bacterial Overgrowth: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 11, 483-490. https://doi.org/10.1016/j.cgh.2012.12.011
[25]
(2020) Expert Consensus on Gastroesophageal Reflux Disease in China in 2020. Chinese Journal of Gastroenterology, 40, 649-663.
[26]
Zheng, Y.-M., Chen, X.-Y., Cai, J.-Y., et al. (2021) Washed Microbiota Transplantation Reduces Proton Pump Inhibitor Dependency in Nonerosive Reflux Disease. World Journal of Gastroenterology, 27, 513-522. https://doi.org/10.3748/wjg.v27.i6.513
[27]
Bajaj, J.S., Barbara, G., Dupont, H.L., et al. (2018) New Concepts on Intestinal Microbiota and the Role of the Non-Absorbable Antibiotics with Special Reference to Rifaximin in Digestive Diseases. Digestive and Liver Disease, 50, 741-749. https://doi.org/10.1016/j.dld.2018.04.020
[28]
Choo, J.M., Kanno, T., Zain, N.M.M., et al. (2017) Divergent Relationships between Fecal Microbiota and Metabolome following Distinct Antibiotic-Induced Disruptions. MSphere, 2, e00005-17. https://doi.org/10.1128/mSphere.00005-17
[29]
Yu, X., Jin, Y., Zhou, W., et al. (2021) Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis without Impacting the Resistome. Frontiers in Cellular and Infection Microbiology, 11, Article 761192. https://doi.org/10.3389/fcimb.2021.761192
[30]
Sharara, A.I., Aoun, F.A.C.P., Abdul-Baki, E., et al. (2006) A Randomized Double-Blind Placebo-Controlled Trial of Rifaximin in Patients with Abdominal Bloating and Flatulence. The American Journal of Gastroenterology, 101, 326-333. https://doi.org/10.1111/j.1572-0241.2006.00458.x
[31]
Tan, V.P.Y., Liu, K.S.H., Lam, F.Y.F., et al. (2017) Randomised Clinical Trial: Rifaximin versus Placebo for the Treatment of Functional Dyspepsia. Alimentary Pharmacology & Therapeutics, 45, 767-776. https://doi.org/10.1111/apt.13945
